Back to results
US 2022/0142989 A1Published application
Detecting and treating growth hormone deficiency
AssigneeLumos Pharma, Inc.
InventorMichael Oliver Thorner
Life of this patent
Estimating the term…
Abstract
Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHM. Also described is a method of treating growth hormone (GH) deficiency (MD) in children with a functional hypothalamic-pituitary GH axis.
Claims16
A method of treating growth hormone deficiency (GHD) in children, comprising:
- administering a therapeutically effective amount of MK-0677 to a child known to have short stature and equivalent growth potential compared to rhGH.
A method of treating GHD in children, comprising:
- a testing a child known to have short stature for GHD using a theranostic test;
- and,
- b orally administering a therapeutically effective amount of MK-0677 to a child found to have short stature and equivalent growth potential compared to rhGH.
A theranostic test, comprising:
- (i.) testing a patient for a peak serum GH≥5 μg/L in response to a single oral dose of MK-0677;
- and,
- (ii.) testing a patient for a baseline serum IGF-I of >30 ng/mL;
method of claim 15, wherein the testing for peak serum, comprises:
- a administering a single, oral dose of MK-0677 to the patient;
- and,
- b testing the GH serum levels achieved after administering MK-0677 to determine the patient's peak serum GH level.
Dependencies are inferred from the claim text.